Cargando…

Clinical features and direct medical cost of splenic injury in China: a cross-sectional study

OBJECTIVES: This study analyses the clinical features and direct medical cost (DMC) of splenic injury during 2000–2013 in China. DESIGN: This was a cross-sectional study. METHODS: We used ‘The No. 1 Military Medical Project’ information system to conduct a retrospective study. Patients’ information...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yong, Liu, Yan, Ma, Yubo, Qi, Yong, Zhang, Qiu, Zhou, Ji-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185598/
https://www.ncbi.nlm.nih.gov/pubmed/35680265
http://dx.doi.org/10.1136/bmjopen-2021-058612
_version_ 1784724760663425024
author Chen, Yong
Liu, Yan
Ma, Yubo
Qi, Yong
Zhang, Qiu
Zhou, Ji-Hong
author_facet Chen, Yong
Liu, Yan
Ma, Yubo
Qi, Yong
Zhang, Qiu
Zhou, Ji-Hong
author_sort Chen, Yong
collection PubMed
description OBJECTIVES: This study analyses the clinical features and direct medical cost (DMC) of splenic injury during 2000–2013 in China. DESIGN: This was a cross-sectional study. METHODS: We used ‘The No. 1 Military Medical Project’ information system to conduct a retrospective study. Patients’ information from 2000 to 2013 were identified. Demographic data, treatment, clinical data and DMC were collected. We performed a generalised linear method (GLM) using gamma distribution to assess the drivers of DMCs. RESULTS: We included 8083 patients with splenic injury who met the study criteria. Over the 14-year study period, 2782 (34.4%) patients were treated with non-operative management (NOM), 5301 (65.6%) with OM. From 2000 to 2013, the rate of NOM increased from 34.7% to 55.9%, while OM decreased from 65.3% to 44.1%. Mean per-patient DMC in both NOM and OM increased from 2000 to 2013. In GLM analysis, male, old age, length of stay, severe splenic injury grade, OM, intensive care unit, blood transfusion and tertiary hospitals were associated with higher DMC, while female and NOM was associated with lower DMC. CONCLUSIONS: In China, management of splenic injury was the most important factor impacting the total DMC. Proper management and public policy could curtail the burden of splenic injury.
format Online
Article
Text
id pubmed-9185598
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91855982022-06-16 Clinical features and direct medical cost of splenic injury in China: a cross-sectional study Chen, Yong Liu, Yan Ma, Yubo Qi, Yong Zhang, Qiu Zhou, Ji-Hong BMJ Open Health Economics OBJECTIVES: This study analyses the clinical features and direct medical cost (DMC) of splenic injury during 2000–2013 in China. DESIGN: This was a cross-sectional study. METHODS: We used ‘The No. 1 Military Medical Project’ information system to conduct a retrospective study. Patients’ information from 2000 to 2013 were identified. Demographic data, treatment, clinical data and DMC were collected. We performed a generalised linear method (GLM) using gamma distribution to assess the drivers of DMCs. RESULTS: We included 8083 patients with splenic injury who met the study criteria. Over the 14-year study period, 2782 (34.4%) patients were treated with non-operative management (NOM), 5301 (65.6%) with OM. From 2000 to 2013, the rate of NOM increased from 34.7% to 55.9%, while OM decreased from 65.3% to 44.1%. Mean per-patient DMC in both NOM and OM increased from 2000 to 2013. In GLM analysis, male, old age, length of stay, severe splenic injury grade, OM, intensive care unit, blood transfusion and tertiary hospitals were associated with higher DMC, while female and NOM was associated with lower DMC. CONCLUSIONS: In China, management of splenic injury was the most important factor impacting the total DMC. Proper management and public policy could curtail the burden of splenic injury. BMJ Publishing Group 2022-06-08 /pmc/articles/PMC9185598/ /pubmed/35680265 http://dx.doi.org/10.1136/bmjopen-2021-058612 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Health Economics
Chen, Yong
Liu, Yan
Ma, Yubo
Qi, Yong
Zhang, Qiu
Zhou, Ji-Hong
Clinical features and direct medical cost of splenic injury in China: a cross-sectional study
title Clinical features and direct medical cost of splenic injury in China: a cross-sectional study
title_full Clinical features and direct medical cost of splenic injury in China: a cross-sectional study
title_fullStr Clinical features and direct medical cost of splenic injury in China: a cross-sectional study
title_full_unstemmed Clinical features and direct medical cost of splenic injury in China: a cross-sectional study
title_short Clinical features and direct medical cost of splenic injury in China: a cross-sectional study
title_sort clinical features and direct medical cost of splenic injury in china: a cross-sectional study
topic Health Economics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185598/
https://www.ncbi.nlm.nih.gov/pubmed/35680265
http://dx.doi.org/10.1136/bmjopen-2021-058612
work_keys_str_mv AT chenyong clinicalfeaturesanddirectmedicalcostofsplenicinjuryinchinaacrosssectionalstudy
AT liuyan clinicalfeaturesanddirectmedicalcostofsplenicinjuryinchinaacrosssectionalstudy
AT mayubo clinicalfeaturesanddirectmedicalcostofsplenicinjuryinchinaacrosssectionalstudy
AT qiyong clinicalfeaturesanddirectmedicalcostofsplenicinjuryinchinaacrosssectionalstudy
AT zhangqiu clinicalfeaturesanddirectmedicalcostofsplenicinjuryinchinaacrosssectionalstudy
AT zhoujihong clinicalfeaturesanddirectmedicalcostofsplenicinjuryinchinaacrosssectionalstudy